Pharmaceutical advertising compliance
Pharmaceutical advertising compliance is a live concern for Technology, AI & Competition firms building or distributing health-adjacent AI tools, programmatic ad platforms, or digital therapeutics. The U.S. Food and Drug Administration's Office of Prescription Drug Promotion and the U.S. Federal Trade Commission both assert authority here: OPDP governs promotional content for prescription products, while the FTC's updated Health Products Compliance Guidance (2022) extends deceptive-advertising liability to AI-generated claims and algorithmic recommendation systems. Tech firms whose platforms surface, optimize, or generate drug-related content are in scope.
Watch
- FTC Health Products Compliance Guidance 2022: AI-generated claims now explicitly covered
- OPDP untitled letters targeting digital platforms distributing off-label promotional content
- Whether your ad-serving algorithm constitutes 'dissemination' under 21 CFR Part 202
- State AG enforcement actions against health-claim targeting on social and search platforms
Recent material activity in Technology, AI & Competition
-
NIST releases updated AI Risk Management Framework companion guide for critical infrastructure
NIST published AI RMF 1.1 companion guidance specifically addressing AI deployment in critical infrastructure sectors including energy, financial services, and healthcare. The guide introduces mandatory risk assessment c…
Read a full sample brief →